Differential Diagnostics of Acute Myeloid Leukaemia

Biotype Diagnostic provides the multiparameter approach Mentype®AMLplexQS for reliable diagnostics of acute myeloid leukaemia (AML). One reaction of this diagnostic test identifies 31 possible gene variations described to be causative for AML. Hence, a rapid and precise aetiology is enabled and supports an early onset of a risk-adopted therapy, which is in urged favour for the patients’ quality of living.

Effective performance ability of this diagnostics is given through simultaneous detection and amplification of several gen segments in one reaction. As a result, hands-on time is reduced to 3 h and ensured results will already be available by the end of a working day. Concomitant and without extra time exposure or additional expenses two internal controls serve as quality insurance within each single reaction. An extra positive control is part of the test design and can be applied on demand. Further, this application can individually be adapted to the respective number of samples that accumulate and require prompt analysis. Thus, even a small quantity of samples can immediately be processed without implying cost intensive losses of material.

In comparison to commonly used single analysis approaches the mutliparameter technology reduces additional costs for lab consumables, prevents time consuming working steps and, not at least, cuts down potential error sources. Determination of several parameters within one reaction thus enables efficient analysis. Especially in case of AML, for which a large number of genetic alterations were found to be causative, a screening tool that sheds light not only on most often, but also on seldom occurring genetic aberrations, is essential for a fast and reliable diagnostic analysis.

Company profile:
Biotype Diagnostic develops molecular biological In-Vitro-Diagnostics (IVD) for medical areas such as Haematology/Oncology, Dermatology and Urology. The company’s know how is built on longstanding experience in developing and manufacturing DNA-analytical test systems.

In close collaboration with academic and clinical partners Biotype continuously transfer scientific know-how into marketable applications to create holistic diagnostics. Thus, the company’s portfolio also includes DNA-extraction systems by which sample preparation can be carried out from diverse biological material.

Mentype®AMLplexQS identifies in one reaction not only most often but also rare genetic aberrations that are causative for AML.

Contact:
Sophia Mersmann
Biotype Diagnostic
Moritzburger Weg 67
D-01109 Dresden
Germany
+49 351 8838 432